Heron Therapeutics

B10 L-BPA Injection is a small-molecule therapeutic candidate developed by Heron Therapeutics for the treatment of meningioma, currently in Phase 2 clinical development. The program is identified by internal code 2024-08-015B and is associated with NCT06668987. As of the latest disclosed milestone on May 11, 2026, the program has completed Phase 2 evaluation, though specific efficacy and safety data have not yet been disclosed. Meningioma represents a significant unmet medical need, particularly for patients with recurrent or progressive disease where treatment options remain limited. Heron Therapeutics' strategy appears focused on advancing a novel small-molecule approach to address this indication. The mechanism of action and specific molecular target for B10 L-BPA Injection have not yet been disclosed. The program operates in a competitive landscape that includes several Phase 2 candidates from other sponsors, including programs from Jazz Pharmaceuticals and investigator-sponsored trials. Regulatory status across major markets including the FDA, EMA, and NMPA remains to be disclosed as development progresses.

Meningioma represents a significant clinical challenge with substantial unmet medical need. While many meningiomas are benign, a substantial proportion are atypical or malignant, with limited effective treatment options beyond surgery and radiation therapy. Recurrent and progressive meningiomas present particular therapeutic challenges, as treatment options become increasingly constrained. The development of novel pharmacological approaches to meningioma addresses a gap in the current treatment armamentarium, particularly for patients who have exhausted or are unsuitable for conventional therapies.

The competitive landscape for meningioma therapeutics is emerging, with multiple Phase 2 programs in development from various sponsors including Jazz Pharmaceuticals (JZP3507, ONC201), investigator-sponsored trials (EORTC 2334-BTG at Ningbo Cancer Hospital), and other small-molecule approaches (Stivarga). This suggests growing recognition of the market opportunity and clinical need. The commercial significance of a successful meningioma therapeutic could be substantial, given the chronic nature of the disease, the need for durable responses, and the limited current options for advanced disease. Patient populations suitable for treatment include those with recurrent, progressive, or inoperable meningiomas across all grades.

B10 L-BPA Injection is classified as a small-molecule therapeutic administered by injection. The specific mechanism of action, molecular target, and therapeutic class have not yet been disclosed by the sponsor. The program is being evaluated as a monotherapy approach in meningioma. Related investigational approaches in the same indication include other small-molecule inhibitors and targeted therapies currently in Phase 2 development. Patent status and first approval information are not yet disclosed.

• Modality: Small-molecule injection
• Indication: Meningioma
• Mechanism of action: Not yet disclosed
• Target: Not yet disclosed
• Route of administration: Injection
• Therapeutic class: Not yet disclosed
• First approval: Not yet disclosed
• Patent status: Not yet disclosed

Regulatory status across major jurisdictions has not yet been disclosed for B10 L-BPA Injection. The program is currently in Phase 2 clinical development, indicating that investigational new drug (IND) or equivalent regulatory authorization has been obtained in at least one jurisdiction, but formal regulatory submissions for approval have not been made. FDA, EMA, PMDA (Japan), and NMPA (China) approval status remain not yet disclosed. The associated clinical trial NCT06668987 is registered with ClinicalTrials.gov, indicating U.S. regulatory engagement. Regulatory pathway and timelines to potential approval are not yet disclosed.

B10 L-BPA Injection represents Heron Therapeutics' entry into the emerging meningioma therapeutics space. The completion of Phase 2 as of May 2026 represents a significant milestone, though the absence of disclosed efficacy and safety data limits assessment of clinical potential at this time. Strategic implications depend heavily on the comparative efficacy profile relative to competing Phase 2 programs, particularly those from Jazz Pharmaceuticals, which has two candidates in development and represents a well-capitalized competitor.

• The injection route of administration may offer advantages in certain patient populations or clinical settings, but could present challenges for chronic dosing compared to oral alternatives if competitors advance oral formulations.
• Key catalysts include disclosure of Phase 2 efficacy and safety data, potential advancement to Phase 3, regulatory feedback meetings, and competitive data readouts from Jazz Pharmaceuticals and other sponsors.
• Commercial success will depend on differentiation from competitors on efficacy, safety, tolerability, and convenience of administration. The meningioma market remains relatively small compared to other oncology indications, but growing recognition of unmet need may expand addressable population.
• Heron Therapeutics' strategy in this indication and potential partnership or licensing arrangements remain to be disclosed.